Institute Springe, German Red Cross Blood Service NSTOB, Springe, Germany.
Br J Haematol. 2013 Aug;162(4):442-54. doi: 10.1111/bjh.12403. Epub 2013 May 27.
The use of pathogen reduction technologies (PRTs) for labile blood components is slowly but steadily increasing. While pathogen-reduced plasma is already used routinely, efficacy and safety concerns impede the widespread use of pathogen-reduced platelets. The supportive and often prophylactic nature of blood component therapy in a variety of clinical situations complicates the clinical evaluation of these novel blood products. However, an increasing body of evidence on the clinical efficacy, safety, cost-benefit ratio and development of novel technologies suggests that pathogen reduction has entered a stage of maturity that could further increase the safety margin in haemotherapy. This review summarizes the clinical evidence on PRTs for plasma and platelet products that are currently licensed or under development.
病原体减少技术（PRTs）在不稳定血液成分中的应用正在缓慢而稳步地增加。虽然已经常规使用病原体减少血浆，但疗效和安全性问题阻碍了病原体减少血小板的广泛应用。在各种临床情况下，血液成分治疗的支持性和预防性性质使这些新型血液产品的临床评估变得复杂。然而，越来越多的关于临床疗效、安全性、成本效益比和新技术发展的证据表明，病原体减少已经进入了一个成熟阶段，这可能会进一步提高血液治疗的安全边际。本综述总结了目前已获得许可或正在开发的血浆和血小板产品的 PRTs 的临床证据。
